C4 Therapeutics, Inc
Biopharmaceutical company focused on developing small molecule medicines to treat cancer and other conditions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying C4 Therapeutics stock, expecting it to rise significantly in value.
Financial Health
C4 Therapeutics is generating reasonable revenue and cash flow, but faces challenges with profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical milestones ahead
Upcoming trial readouts can move the stock substantially; positive data may unlock partnerships, though outcomes are binary and uncertain.
Novel therapeutic approach
Targeted protein degradation offers access to previously hard‑to‑drug targets, but scientific and regulatory hurdles remain.
Financing and runway
As a small‑cap biotech, C4 will likely need capital over time; that can enable development but may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
